Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway
Clinical Rheumatology · 2026
DOI: 10.1007/s10067-026-08313-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Jimei Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi Province, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Signal Transduction, Janus Kinase 2, Arthritis, Experimental. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Fundamental Research Program of Shanxi Province, Shanxi Province Traditional Chinese Medicine Research Project.
Abstract (Originalsprache)
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent inflammation and progressive joint destruction, in which aberrant activation of the JAK/STAT signaling pathway plays a central pathogenic role. Although JAK inhibitors are utilized in clinical practice, emerging limitations such as potential resistance underscore the need to identify novel therapeutic modulators. Reticuline, a natural isoquinoline alkaloid, has not been systematically investigated for its anti‑arthritic efficacy or mechanism of action.
Methods
In this study, we integrated network pharmacology, molecular docking, in vitro assays, and a collagen‑induced arthritis (CIA) mouse model to comprehensively evaluate the therapeutic potential of reticuline and elucidate its underlying mechanisms.
Results
Network analysis predicted the JAK‑STAT pathway as a primary pathway involved. Molecular docking results suggested that reticuline could potentially bind to the ATP-binding pocket of JAK2, forming five hydrogen bonds. In TNF‑α‑stimulated human synovial fibroblasts (MH7A), reticuline (10 and 20 µM) significantly suppressed cell migration and intracellular ROS generation, downregulated IL‑6 mRNA, and upregulated IL‑10 and IL-1β mRNA expression. Importantly, reticuline markedly inhibited the phosphorylation and mRNA expression of JAK2 and STAT3. In CIA mice, reticuline administration (0.5 and 1 mg/kg/day) substantially reduced clinical arthritis scores, synovial hyperplasia, and bone erosion, while modulating serum cytokine profiles (lowering TNF‑α, IL‑1β, and IL‑17, and elevating IL‑10). Consistent with the cellular findings, reticuline also attenuated activation of the JAK2/STAT3 pathway in joint tissues.
Conclusion
In summary, this work provides the first systematic preclinical evidence that reticuline ameliorates RA pathology by suppressing the JAK2/STAT3 signaling cascade, positioning it as a promising preclinical candidate, providing a foundation for further translational development of reticuline for RA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi Province, China.
- Shanxi Provincial Department, Municipal Key Laboratory Cultivation Base for Quality Enhancement and Utilization of Shangdang Chinese Medicinal Materials, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi Pr…
- Department of Rheumatology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi Province, China. 18235524315@163.com.
Förderung
- Fundamental Research Program of Shanxi Province
- Shanxi Province Traditional Chinese Medicine Research Project
Zitieren
APA
Tian, J., Zhang, J., Yang, Y., Song, Y., Yuan, Z., & Chang, S. (2026). Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08313-6
Vancouver
Tian J, Zhang J, Yang Y, Song Y, Yuan Z, Chang S. Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08313-6
BibTeX
@article{Tian2026,
author = {Tian, Jimei and Zhang, Jinyu and Yang, Yibo and Song, Yali and Yuan, Ziqi and Chang, Sheng},
title = {Reticuline alleviates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway},
journal = {Clinical Rheumatology},
year = {2026},
doi = {10.1007/s10067-026-08313-6}
}
EUVIMED